Complement Inhibitor

Complement Inhibitors

Hemoglobinuria, Paroxysmal

Atypical Hemolytic Uremic Syndrome

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Eculizumab, a complement inhibitor, is a recombinant humanized monoclonal IgG2/4<span class="Sub">κ</span> antibody produced by murine myeloma cell culture and purified by standard bioprocess technology.  Eculizumab contains human constant regions from human IgG2 sequences and human IgG4 sequences and murine complementarity-determining regions grafted onto the human framework light- and heavy-chain variable regions.  Eculizumab is composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148 kDa.</p><p>SOLIRIS (eculizumab) injection is a sterile, clear, colorless, preservative-free 10 mg/mL solution for intravenous infusion and is supplied in 30-mL single-dose vials. The product is formulated at pH 7 and each 30 mL vial contains 300 mg of eculizumab, polysorbate 80 (6.6 mg) (vegetable origin), sodium chloride (263.1 mg), sodium phosphate dibasic (53.4 mg), sodium phosphate monobasic (13.8 mg), and Water for Injection, USP.</p></section>

SOLIRIS

eculizumab

Soliris

30 ML eculizumab 10 MG/ML Injection

30 ML eculizumab 10 MG/ML Injection [Soliris]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide

Submit MSL Request

Pharmacy List

Reimbursement Information

Alexion Access Navigator (All Indications) - HCP 

Access & Reimbursement Guide - All Indications

Reauthorization Guide - All Indications

Billing & Coding Guide: AChR Antibody Positive Generalized Myasthenia Gravis (gMG)

Billing & Coding Guide: AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Billing & Coding Guide: Atypical Hemolytic Uremic Syndrome (aHUS)

Billing & Coding Guide: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Coverage Authorization Request 

Coverage Authorization Appeal: AChR Antibody Positive Generalized Myasthenia Gravis (gMG)

Letter of Medical Necessity: AChR Antibody Positive Generalized Myasthenia Gravis (gMG)

PA Criteria: AChR Antibody Positive Generalized Myasthenia Gravis (gMG)

Coverage Authorization Appeal: AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Letter of Medical Necessity: AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Letter of Medical Necessity: Atypical Hemolytic Uremic Syndrome (aHUS)

Coverage Authorization Appeals: Paroxysmal Nocturnal Hemoglobinuria (PNH) 

Letter of Medical Necessity: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Enroll in Patient Savings Program

Vaccinations: AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Other HCP Resources: AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Soliris Infusion Locator

About Soliris: AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Soliris Start Guide: AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Patient Resources: AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Patient Brochure: AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Patient Brochure (Spanish): AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Doctor Discussion Guide: AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Patient Safety Card: AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Alexion OneSource Support Program - All Indications

Instructions For Use:  AChR Antibody Positive Generalized Myasthenia Gravis (gMG)

Instructions For Use: AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

Instructions For Use: Atypical Hemolytic Uremic Syndrome (aHUS)

Instructions For Use: Paroxysmal Nocturnal Hemoglobinuria (PNH)